<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83726">
  <stage>Registered</stage>
  <submitdate>16/03/2009</submitdate>
  <approvaldate>15/05/2009</approvaldate>
  <actrnumber>ACTRN12609000278235</actrnumber>
  <trial_identification>
    <studytitle>The effect of zoledronate on cardiovascular protection in osteoporotic elderly patients who have suffered a hip fracture.</studytitle>
    <scientifictitle>A randomised, double-blind, placebo-controlled trial to determine the effect of zoledronate on endothelial dysfunction in osteoporotic elderly patients who have suffered a hip fracture</scientifictitle>
    <utrn />
    <trialacronym>ZED</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endothelial Dysfunction</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Zoledronic acid 5 mg in 100 mL, intravenous, infused over 30 minutes, single dose.</interventions>
    <comparator>Placebo (saline), 100 mL, intravenous, infused over 30 minutes, single dose.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in markers of Endothelial Dysfunction induced after administration of Zoledronate in elderly patients who have suffered a hip fracture. Markers of endothelial dysfunction will include: capillaroscopy, serum levels of nitric oxide, and quantification of  receptor activator of NFkappaB ligand (RANK-L) in circulating lymphocytes.</outcome>
      <timepoint>Before infusion
Immediately after infusion
6 months after infusion
1 year after infusion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Death due to cardiovascular event
Cardiovascular event (myocardial infarction (MI), cerebrovascular accident (CVA))</outcome>
      <timepoint>1 year after infusion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1- Diagnosis of osteoporosis based on bone mineral density (BMD)
2- Previous history of hip fracture a year prior to the administration of the dose</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1)	creatinine clearance &lt; 35 ml/min
2)	pre-existing hypocalcemia must be treated by adequate intake of calcium and vitamin D before therapy with zoledronic acid
3)	active history of uveitis, iritis, or episcleritis 
4)	metastatic cancer or cancer diagnosed less than 2 years ago where treatment is still ongoing
5)	History of diabetes mellitus
6)	Active primary hyperparathyroidism
7)	Hypothyroidism, not appropriately controlled with long-term thyroxine therapy
8)	Serum 25-hydroxyvitamin D concentrations &lt;15 ng/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Medication will be prepared by a doctor not involved with study participants. The medication will be then administered by a study nurse who is unaware of the contents. Thus all study personnel with patient contact will be blinded.</concealment>
    <sequence>Computer-generated random numbers in variable blocks.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2750</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof. Gustavo Duque</primarysponsorname>
    <primarysponsoraddress>Nepean Clinical School
PO Box 63
Penrith, NSW, 2751</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharmaceuticals</fundingname>
      <fundingaddress>Novartis Pharmaceuticals Australia Pty Ltd
54, Waterloo Road
North Ryde, NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Sydney</sponsorname>
      <sponsoraddress>Level 5, South Block
Nepean Hospital
Penrith, NSW, 2750</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a one year study to identify the effect of Zoledronate on endothelial dysfunction, a marker or cardiovascular risk.</summary>
    <trialwebsite>http://www.test.agingbone.med.usyd.edu.au/research/clinical-trials/zoledronic-acid/index.php</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney West Area of Health Services (SWAHS) Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>21/03/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Gustavo Duque</name>
      <address>Aging Bone Research Program
Nepean Clinical School
PO Box 63
Penrith, NSW, 2751</address>
      <phone>+61 2 4734 4278</phone>
      <fax>+61 2 4734 1817</fax>
      <email>gduque@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Griselda Loza-Diaz</name>
      <address>Nepean Clinical School
Aging Bone Research Program
PO Box 63
Penrith, NSW, 2751</address>
      <phone>+61 2 4734 4278</phone>
      <fax>+61 2 4734 1817</fax>
      <email>griselda.loza-diaz@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Griselda Loza-Diaz</name>
      <address>Aging Bone Research Program Nepean Clinical School
PO Box 63, Penrith, NSW 2750</address>
      <phone>+61247341772</phone>
      <fax>+61247341817</fax>
      <email>griselda.loza-diaz@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Gustavo Duque</name>
      <address>Aging Bone Research Program Nepean Clinical School
PO Box 63
Penrith, NSW, 2750</address>
      <phone>+61247344278</phone>
      <fax />
      <email>gustavo.duque@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>